The Fluid Expansion as Supportive Therapy (FEAST) study, conducted in Africa, found an increased risk of death among children with sepsis who received early treatment with bolus 5% albumin or 0.9% saline, in comparison with the control group [105]. This evidence concerns the gene ALB and Sepsis.